FOI Foccini International

Foccini International Inc. ("Foccini" or the "Company")(TSX VENTURE:FOI)
announces it has acquired options to purchase 100% ownership of two Alberta
based biotechnology companies. Both options expire on April 30, 2010. These
companies, named 1495628 Alberta Ltd. and 1502440 Alberta Ltd respectively, are
in addition to the previously announced pending acquisition of Arch Biotech Inc.
("Arch"), a private company specializing in biomedical technology and drug
development.


The Company announced on December 18, 2009 it has submitted a change of
business/reverse takeover application ("Transaction") to the TSX Venture
Exchange (the "TSXV") and pursuant to TSXV Policy 5.2 - Changes of Business and
Reverse Takeovers. Foccini has notified the TSXV it intends to exercise the
options to acquire the two new Alberta corporations and to include them in the
Transaction as "Concurrent Acquisitions" to the Arch acquisition. 


The final closing of the Transaction will depend on all regulatory and
shareholder approvals.


Terms of the Option to Acquire 1495628 Alberta Ltd

The Company has agreed to pay approximately $20,000 in legal and patent fees on
behalf of 1495628 Alberta Ltd. in consideration for the option. 


Upon exercise of the option and the receipt of all necessary approvals, the
Company will issue a total of 2,146,000 common shares in the capital of the
Company (each, a "Common Share") to the shareholders of 1495628 Alberta Ltd. at
a deemed price of $0.50 per share for a total value of $1,073,000 in return for
all of the issued and outstanding shares in the capital of 1495628 Alberta Ltd.


About 1495628 Alberta Ltd.

1495628 Alberta Ltd. is a private company and was incorporated under the ABCA in
October, 2009 to hold legal and beneficial title to the intellectual property
produced by Dr. Randall Irvin and colleagues at the University of Alberta in
connection with a research project specializing in peptide chemistry. The
principal asset of 1495628 Alberta Ltd. presently consists of a provisional
patent filed with the United States Patent and Trademarks Office relating to
intellectual property developed by Dr. Irvin, Dr. D.Y. Li and Elisabeth Davis in
the area of interfacing biological compounds and solid surfaces. The foregoing
provisional patent was transferred and assigned to 1495628 Alberta Ltd. pursuant
to the terms of an intellectual property transfer agreement between 1495628
Alberta Ltd., Dr. Irvin, Dr. Li, Elisabeth Davis and the University of Alberta.


The proposed distribution of Common Shares pursuant to the terms of the 1495628
Alberta Option and Purchase Agreement is as follows:




---------------------------------------------------------------------------
Dr. Randall Irvin                                   1,500,000 Common Shares
Dr. D.Y. Li                                           186,700 Common Shares
Elisabeth Davis                                       186,700 Common Shares
University of Alberta                                 272,600 Common Shares
---------------------------------------------------------------------------
                  Total                             2,146,000 Common Shares
---------------------------------------------------------------------------



Terms of the Option to Acquire 1502440 Alberta Ltd

The Company has agreed to pay approximately $20,000 in legal and patent fees on
behalf of 1502440 Alberta Ltd. in consideration for the option. 


Upon exercise of the option and the receipt of all necessary approvals, the
Company will issue a total of 1,667,000 Common Shares to the shareholders of
1502440 Alberta Ltd. at a deemed price of $0.50 per share for a total value of
$833,500 in return for all of the issued and outstanding shares in the capital
of 1502440 Alberta Ltd.


About 1502440 Alberta Ltd.

1502440 Alberta Ltd. is a private company and was incorporated under the ABCA
during January 2010 to hold legal and beneficial title to the intellectual
property produced by Dr. Stephen Robbins, Dr. Donna Senger and colleagues at the
University of Calgary in connection with a research project specializing in
brain cancer stem cells. The principal asset of 1502440 Alberta Ltd. presently
consists of a provisional patent filed with the United States Patent and
Trademarks Office relating to intellectual property developed by Dr. Robbins,
Dr. Senger and Dr. Jennifer Rahn in the area of brain cancer stem cells. The
foregoing provisional patent was transferred and assigned to 1502440 Alberta
Ltd. pursuant to the terms of an intellectual property transfer agreement
between 1502440 Alberta Ltd. and Dr. Robbins, Dr. Senger and Dr. Rahn.


The proposed distribution of Common Shares pursuant to the terms of the 1502440
Alberta Option and Purchase Agreement is as follows:




---------------------------------------------------------------------------
Dr. Stephen Robbins                                   750,000 Common Shares
Dr. Donna Senger                                      750,000 Common Shares
Dr. Jennifer Rahn                                     167,000 Common Shares
---------------------------------------------------------------------------
                  Total                             1,667,000 Common Shares
---------------------------------------------------------------------------



Current Status of the Company's Reverse Takeover Application

The Company currently awaits feedback from the TSXV on the application it
submitted on December 18, 2009 regarding the proposed Transaction. The Company
is seeking Conditional Approval from the TSXV before proceeding with a special
meeting of shareholders wherein shareholders of Foccini will be asked to
consider and vote on a securities exchange transaction between the Company, Arch
Biotech Inc. ("Arch"), the University of Calgary and the shareholders of Arch
(the "Arch Acquisition Transaction") whereby, among other things, the Company
will acquire all of the issued and outstanding shares in the capital of Arch in
exchange for a total of 15,776,000 Common Shares. The Company also intends to
close: (i) the two separate acquisitions of 1495628 Alberta Ltd. and 1502440
Alberta Ltd. resulting in the issuance of an aggregate of 3,813,000 Common
Shares (the "Concurrent Acquisitions"), and (ii) a non-brokered private
placement of 10,000,000 Common Shares for gross proceeds of up to $5,000,000
(the "Concurrent Private Placement"). 


Foccini currently has 26,371,179 Common Shares issued and outstanding. Foccini
proposes to issue an aggregate of 29,589,000 Common Shares in connection with
the completion of the Arch Acquisition Transaction, Concurrent Acquisitions and
Concurrent Private Placement. As a result, the current shareholders of Foccini
will own, in the aggregate, approximately 47.12% of the issued and outstanding
Common Shares on a non-diluted basis. Accordingly, the Company has proposed to
the TSXV that the completion of the Arch Acquisition Transaction, the Concurrent
Acquisitions and Concurrent Private Placement will constitute a reverse takeover
of Foccini in as much as the former Arch shareholders, former shareholders of
1495628 Alberta Ltd. and 1502440 Alberta Ltd. and the new shareholders of
Foccini who subscribed for Common Shares pursuant to the Concurrent Private
Placement will own 52.88% of the issued and outstanding Common Shares on a
non-diluted basis. Moreover, three of the four members of the board of directors
of the Resulting Issuer and all members of the proposed scientific advisory
board of the Resulting Issuer will be designees of Arch.


Completion of the Transaction is subject to a number of conditions, including
Exchange acceptance and disinterested Shareholder approval. The Transaction
cannot close until the required Shareholder approval is obtained. There can be
no assurance that the Transaction will be completed as proposed or at all.


Investors are cautioned that, except as disclosed in a Management Information
Circular to be prepared in connection with the Transaction, any information
released or received with respect to the Change of Business may not be accurate
or complete and should not be relied upon. Trading in the securities of Foccini
International Inc should be considered highly speculative.


The TSX Venture Exchange has in no way passed upon the merits of the proposed
transaction and has neither approved nor disapproved the contents of this press
release.


For more information on the Company, please consult the other public documents
including all press releases, financial statements and management discussion and
analysis filed on SEDAR at www.sedar.com


Forward-Looking Statements

All statements, other than statements of historical fact, in this news release
are forward looking statements that involve various risks and uncertainties,
including, without limitation, statements regarding the future plans and
objectives of the Company. There can be no assurance that such statements will
prove to be accurate. Actual results and future events could differ materially
from those anticipated in such statements. These and all subsequent written and
oral forward-looking statements are based on the estimates and opinions of
management on the dates they are made and are expressly qualified in their
entirety by this notice. The Company assumes no obligation to update
forward-looking statements should circumstances or management's estimates or
opinions change.

Foccini International (TSXV:FOI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

Foccini International (TSXV:FOI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024